Skip to main content

Table 2 Cellularity of bronchoalveolar lavage fluid (BALF) and peripheral blood in all patients, survivors, non-survivors and univariate analysis

From: Bronchoalveolar lavage fluid characteristics and outcomes of invasively mechanically ventilated patients with COVID-19 pneumonia in Genoa, Italy

  All patients
(n = 64)
Survivors
(n = 43)
(67.2%)
Non-survivors
(n = 21)
21 (32.8%)
P
Cellularity of BALF
 Lymphocytes %, median (IQRb) 1 (0.4–3.75) 1 (0.3–2.25) 1 (1–4) 0.502
 Neutrophils %, median (IQR) 70 (37.5–90.5) 71 (46–90.5) 63 (36–83.5) 0.408
 Macrophages %, median (IQR) 20 (7–42) 20 (7–42) 35 (16.5–56.7) 0.194
 TCD3+ %, median (IQR) 92(82–95) 92 (83–94) 89 (79–96) 0.873
 TCD4+ %, median (IQR) 30 (22–46.5) 31 (22–47) 29 (23–39) 0.976
 TCD8+ %, median (IQR) 52 (39.5–62.7) 53 (37–60) 46 (42–64) 0.995
 TCD4+/TCD8+ Ratio 0.6 (0.4–1.2) 0.6 (0.4–1.2) 0.5 (0.3–0.8) 0.495
 B CD19+ %, median (IQR) 2 (1–5) 2.5 (1–5) 1 (1–5) 0.205
 Natural Killer (CD56 + CD16+) %, median (IQR) 3 (2–10) 5 (2–10) 3 (2.7–13.7) 0.618
Peripheral blood values at time of BALFa performing
 Lymphocytes/mmc, median (IQR) 630 (475–1000) 900 (500–1220) 520 (340–622) 0.012
 TCD4+/mmc, median (IQR) 317 (190–534) 358 (236–651) 227 (152–430) 0.100
 TCD8+/mmc, median (IQR) 82 (39–235) 160 (63–267) 44 (29–87) 0.007
 R TCD4+/TCD8+, median (IQR) 4.1 (2–5.5) 3.2 (1.4–5) 5 (3.6–6.4) 0.430
  1. aBALF bronchoalveolar lavage fluid, bIQR interquartile range